IGF1 and breast carcinoma: Ligands that bind to ErbB receptors were the most broadly active (every tested ErbB ligand elicited a significant response in at least 35 lines), followed by FGF-1/2, HGF, and IGF-1/2, consistent with the known importance of these ligands in breast cancer biology.